Nicotine gum (C) — Competitive Intelligence Brief

Nicotine gum (C) (Nicotine gum (C)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicotine gum (C) (Nicotine gum (C)) — 22nd Century Group, Inc.. Nicotine gum delivers nicotine through the oral mucosa to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine gum (C) TARGET	Nicotine gum (C)	22nd Century Group, Inc.	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Patch, Nicotine	Patch, Nicotine	Assistance Publique - Hôpitaux de Paris	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Spinosad Topical	Spinosad Topical	Cipher Pharmaceuticals Inc.	marketed	Natural insecticide	Nicotinic acetylcholine receptors; GABA-gated chloride channels
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine Patch and Nicotine Lozenge	Nicotine Patch and Nicotine Lozenge	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Transdermal nicotine patch	Transdermal nicotine patch	University of Pennsylvania	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Combination Bupropion + NRTs	Combination Bupropion + NRTs	Brentwood Biomedical Research Institute	marketed	Antidepressant + nicotine replacement combination	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acetylcholine receptor agonist class)

1. University of Wisconsin, Madison · 3 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. VA Office of Research and Development · 2 drugs in this class
4. Iowa City Veterans Affairs Medical Center · 1 drug in this class
5. Johns Hopkins University · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. 22nd Century Group, Inc. · 1 drug in this class
8. University of Auckland, New Zealand · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Miami · 1 drug in this class